Zobrazeno 1 - 10
of 17
pro vyhledávání: '"A. M. Pristrom"'
Autor:
V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, E. P. Ilivanova, A. V. Strelkova, V. V. Tyrenko, E. A. Mikhailova, A. V. Eremeeva
Publikováno v:
Современная ревматология, Vol 18, Iss 1, Pp 35-46 (2024)
The article presents the results of the three-year use of netakimab (NTK) in patients with ankylosing spondylitis (AS) as part of the phase III BCD-085-5/ASTERA study.Objective: to evaluate the long-term efficacy and safety of NTK over a three-year p
Externí odkaz:
https://doaj.org/article/35b1cb81150247aab4f58712cc2503b9
Autor:
T. V. Dubinina, A. B. Demina, E. M. Agafonova, Sh. F. Erdes, V. I. Mazurov, I. Z. Gaydukova, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, V. V. Tyrenko, E. P. Ilivanova, A. V. Strelkova
Publikováno v:
Современная ревматология, Vol 17, Iss 6, Pp 52-58 (2023)
The article contains the data obtained during the 156-week follow-up of patients with ankylosing spondylitis (AS) in the ASTERA phase III study.Objective: to evaluate the effect impact of netakimab (NTK) on quality of life (QoL), back pain and work c
Externí odkaz:
https://doaj.org/article/21939fb7c39048f99cdce239380dea45
Autor:
V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, E. P. Ilivanova, A. V. Strelkova, A. V. Eremeeva, A. V. Zinkina-Orikhan
Publikováno v:
Современная ревматология, Vol 14, Iss 4, Pp 39-49 (2020)
Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic arthritis, and plaque psoriasis. The paper gives the data obtained during 52-week follow-up o
Externí odkaz:
https://doaj.org/article/984673a23dad4308b93cdaa2748700af
Autor:
V. I. Mazurov, I. Z. Gaydukova, Sh. Erdes, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tciupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, V. V. Tyrenko, E. P. Ilivanova, A. V. Strelkova, A. V. Eremeeva
Publikováno v:
Научно-практическая ревматология, Vol 58, Iss 4, Pp 376-386 (2020)
Netakimab (NTK) is a humanized monoclonal antibody targeting interleukin-17A.Objective. The main objective of BCD-085-5/ASTERA study was to prove superiority of NTK over placebo and assess its’ safety in patients with active AS.Subjects and methods
Externí odkaz:
https://doaj.org/article/7a1a0bd45df54172a1cd35efba011387
Autor:
Sh. Erdes, V. I. Mazurov, T. V. Dubinina, I. Z. Gaydukova, S. A. Lapshina, E. V. Zonova, D. G. Krechikova, T. V. Plaksina, O. V. Reshetko, S. A. Smakotina, P. А. Shesternya, I. G. Gordeev, T. G. Makulova, T. V. Povarova, T. A. Raskina, N. F. Soroka, A. M. Pristrom, E. V. Kunder, Yu. V. Usacheva, E. Yu. Stukalina, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov
Publikováno v:
Научно-практическая ревматология, Vol 57, Iss 6, Pp 668-677 (2019)
The paper presents the results of a double-blind (BCD-085-3/AILAS) phase II clinical trial of the original interleukin 17A (IL17A) inhibitor BCD-085 prescribed at different doses to patients with active ankylosing spondylitis (AS) and those of an ext
Externí odkaz:
https://doaj.org/article/d4904fdfb8d74d86b07500bfba5201ae
Autor:
D. E. Karateev, V. I. Mazurov, E. V. Zonova, O. B. Nesmeyanova, T. V. Plaksina, D. G. Krechikova, O. V. Reshetko, L. N. Denisov, I. G. Gordeev, T. G. Pokrovskaya, O. V. Antipova, T. V. Kropotina, T. V. Povarova, P. A. Shesternya, E. N. Ushakova, N. F. Soroka, A. M. Pristrom, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov, U. V. Usacheva
Publikováno v:
Современная ревматология, Vol 11, Iss 3, Pp 14-25 (2017)
This article presents results from two clinical trials of infliximab biosimilar, BCD-055, including comparative data on the pharmacokinetics (PK), efficacy and safety of BCD-055 and innovator infliximab (IFX) in patients with ankylosing spondylitis (
Externí odkaz:
https://doaj.org/article/305ff993592e47ac835d9cdc1c914e7b
Autor:
E. L. Nasonov, E. V. Zonova, O. N. Ivanova, L. A. Knyazeva, V. I. Mazurov, R. R. Samigullina, I. M. Marusenko, O. B. Nesmeyanova, T. V. Plaksina, A. E. Sizikov, D. G. Krechikova, N. A. Petrochenkova, Yu. S. Shapovalova, N. S. Soroka, S. I. Pimanov, A. M. Pristrom, E. V. Kunder, E. V. Chernyaeva, A. V. Eremeeva, R. Ivanov
Publikováno v:
Научно-практическая ревматология, Vol 54, Iss 5, Pp 510-519 (2016)
The article considers the results of an international multicenter randomized clinical trial of the efficacy and safety of the brand-name drug rituximab (MabThera), a monoclonal antibody against CD20 antigen of B cells, and its biosimi-lar drug (Acell
Externí odkaz:
https://doaj.org/article/1851db3d61f34b5b9904808e9377604d
Autor:
A. V. Korotaev, A. M. Pristrom, E. P. Naumenko, S. N. Korzheva, L. F. Larenko, Ya. L. Navmenova
Publikováno v:
Medical and Biological Problems of Life Activity. :62-66
As a result of a two-year prospective study, the differences between intraventricular and interventricular dyssynchrony in patients with arterial hypertension, atherosclerotic and postinfarction cardiosclerosis were determined according to the data o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5d2e5940beeb987ed94226e973c2638
https://doi.org/10.58708/2074-2088.2023-1(29)-62-66
https://doi.org/10.58708/2074-2088.2023-1(29)-62-66
Autor:
N. Soroka, E. S. Zhugrova, S A Lapshina, D. G. Krechikova, E. P. Ilivanova, T. V. Plaksina, O B Nesmeyanova, E. Kunder, A. M. Pristrom, Diana Abdulganieva, O. V. Antipova, T. V. Kropotina, O. A. Tciupa, Inna Gaydukova, Elena A Smolyarchuk, I. G. Gordeev, Pavel Shesternya, V. V. Tyrenko, Mazurov Vi, Sh F Erdes, Tatiana Dubinina, T. V. Povarova, A. Eremeeva, A. V. Strelkova, A. Kastanayan
Publikováno v:
Научно-практическая ревматология, Vol 58, Iss 4, Pp 376-386 (2020)
Netakimab (NTK) is a humanized monoclonal antibody targeting interleukin-17A.Objective. The main objective of BCD-085-5/ASTERA study was to prove superiority of NTK over placebo and assess its’ safety in patients with active AS.Subjects and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1bf23545fe52209a18611f1b084724b
https://rsp.mediar-press.net/rsp/article/view/2925
https://rsp.mediar-press.net/rsp/article/view/2925
Publikováno v:
Health and Ecology Issues. :39-43
Objective: to assess results of ultrasonography of the thickness of subcutaneous and preperitoneal fat in women with components of metabolic syndrome in the first trimester of pregnancy (n = 143). Material and methods. Anthropometrical parameters, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6c696cd6c506ce343dead79b6089249
https://doi.org/10.51523/2708-6011.2018-15-2-8
https://doi.org/10.51523/2708-6011.2018-15-2-8